Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
Psyence BioMed announced the dosing of the first patient in its Phase IIb clinical trial for NPX-5, a nature-derived psilocybin candidate, to treat Adjustment Disorder in cancer patients in palliative care. This marks the initial large-scale clinical evaluation of NPX-5 across an expanded Australian site network, aiming to assess its safety and therapeutic potential. The study expects to generate data on clinical response, safety, tolerability, and treatment durability to inform future development strategies.
NOV 20·Benzinga▲
Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets - Psyence Biomedical ( NASDAQ:PBM )
NEW YORK, Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- Psyence Biomedical Ltd. ( NASDAQ:PBM ) ( "Psyence BioMed" or the "Company" ) , a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced it had established a sustainable ...
NOV 3·GlobeNewswire▲
Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment
NEW YORK, Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Psyence Biomedical Ltd. ( Nasdaq: PBM ) ( "Psyence BioMed" or the "Company" ) , a biopharmaceutical company advancing nature-derived psilocybin and Ibogaine therapies for unmet mental health needs, today announced it has made a USD$3,500,000 ...
